126 related articles for article (PubMed ID: 1431308)
1. Different interactions of interferon-alpha subtypes at the surface of epithelial and lymphoid cells.
Overall ML; Chambers P; Hertzog PJ
J Interferon Res; 1992 Aug; 12(4):281-8. PubMed ID: 1431308
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of interferon-alpha subtypes using monoclonal antibodies to interferon-alpha 4a--subtype reactivity, neutralisation of biological activities and epitope analysis.
Overall ML; Hertzog PJ
Mol Immunol; 1992 Mar; 29(3):391-9. PubMed ID: 1372957
[TBL] [Abstract][Full Text] [Related]
3. The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation.
Novick D; Nabioullin RR; Ragsdale W; McKenna S; Weiser W; Garone L; Burkins C; Kim SH; Rubinstein M; Tepper MA; Arulanandam AR
J Interferon Cytokine Res; 2000 Nov; 20(11):971-82. PubMed ID: 11096454
[TBL] [Abstract][Full Text] [Related]
4. [Studies on the antitumor activity of human recombinant interferon alpha-2b in vitro].
Haraguchi S; Koide Y; Matsuo T; Yoshida TO
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3236-43. PubMed ID: 2946265
[TBL] [Abstract][Full Text] [Related]
5. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
[TBL] [Abstract][Full Text] [Related]
6. Localization of the receptor binding site of IFN-alpha 2b.
Siemers R; Hensley L; Ozer H
J Immunol; 1988 Sep; 141(5):1550-5. PubMed ID: 2970505
[TBL] [Abstract][Full Text] [Related]
7. Different functional sites on rIFN-alpha 2 and their relation to the cellular receptor binding site.
Cebrián M; Yagüe E; de Landázuri MO; Rodíguez-Moya M; Fresno M; Pezzi N; Llamazares S; Sánchez-Madrid F
J Immunol; 1987 Jan; 138(2):484-90. PubMed ID: 2432126
[TBL] [Abstract][Full Text] [Related]
8. Comparative antiproliferative and receptor binding activities of interferons alpha and beta on lymphoblastoid and melanoma cells.
Hertzog PJ; Johns TG; Callister KA; Dinatale A; Linnane AW
Biochem Int; 1990 Dec; 22(6):1095-102. PubMed ID: 2151021
[TBL] [Abstract][Full Text] [Related]
9. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a domain of a human type I interferon receptor protein involved in ligand binding.
Eid P; Tovey MG
J Interferon Cytokine Res; 1995 Mar; 15(3):205-11. PubMed ID: 7584665
[TBL] [Abstract][Full Text] [Related]
11. Are the acid-labile interferon alpha and interferon omega-1 identical?
Kontsek P; Borecký L; Novák M
Virology; 1991 Mar; 181(1):416-8. PubMed ID: 1994590
[TBL] [Abstract][Full Text] [Related]
12. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies.
Viscomi GC; Antonelli G; Bruno C; Scapol L; Malavasi F; Funaro A; Simeoni E; Pestka S; De Pisa F; Dianzani F
J Interferon Cytokine Res; 1999 Apr; 19(4):319-26. PubMed ID: 10334382
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the binding of radioiodinated hybrid recombinant IFN-alpha A/D to murine and human lymphoid cell lines.
Faltynek CR; Princler GL; Schwabe M; Shata MT; Lewis GK; Kamin-Lewis RM
J Interferon Res; 1990 Feb; 10(1):55-64. PubMed ID: 2139461
[TBL] [Abstract][Full Text] [Related]
14. Evidence for multiple binding sites for several components of human lymphoblastoid interferon-alpha.
Hu R; Gan Y; Liu J; Miller D; Zoon KC
J Biol Chem; 1993 Jun; 268(17):12591-5. PubMed ID: 8509399
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
Johns TG; Mackay IR; Callister KA; Hertzog PJ; Devenish RJ; Linnane AW
J Natl Cancer Inst; 1992 Aug; 84(15):1185-90. PubMed ID: 1378904
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
[TBL] [Abstract][Full Text] [Related]
17. Localization of a receptor nonapeptide with a possible role in the binding of the type I interferons.
Eid P; Langer JA; Bailly G; Lejealle R; Guymarho J; Tovey MG
Eur Cytokine Netw; 2000 Dec; 11(4):560-73. PubMed ID: 11125298
[TBL] [Abstract][Full Text] [Related]
18. Immunochemical mapping of alpha-2 interferon.
Lydon NB; Favre C; Bove S; Neyret O; Benureau S; Levine AM; Seelig GF; Nagabhushan TL; Trotta PP
Biochemistry; 1985 Jul; 24(15):4131-41. PubMed ID: 2413884
[TBL] [Abstract][Full Text] [Related]
19. Binding of human alpha-interferons to natural killer cells.
Langer JA; Ortaldo JR; Pestka S
J Interferon Res; 1986 Apr; 6(2):97-105. PubMed ID: 2941494
[TBL] [Abstract][Full Text] [Related]
20. Differential neutralizing activity of human antibodies in interferon antiviral and natural killer cell bioassays.
Thurmond LM; Reese MJ
J Interferon Cytokine Res; 1997 Oct; 17(10):619-23. PubMed ID: 9355963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
